Vaccine supply chains disrupted by U.S. restrictions: Curevac co-founder
FILE PHOTO: A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves H
BERLIN (Reuters) - Global supply chains for making COVID-19 vaccines have been disrupted by U.S. restrictions, creating headaches for companies seeking to build production in Europe, according to one of the founders of Germany's Curevac.
Florian von der Muelbe said in a newspaper interview that he was hopeful Curevac's vaccine candidate would win emergency European approval this quarter and confirmed a forecast that it would produce 300 million doses this year.
He added, however, that vaccine makers seeking to build production in Europe were at a serious disadvantage because suppliers in the United States were required under the Defense Production Act to meet the needs of the home market first.
"Global supply chains are disrupted," von der Muelbe, now Curevac's chief production officer, told the Rheinische Post in an interview published on Wednesday.
"Be it chemicals, equipment, filters or hoses: U.S. manufacturers are obliged first to meet American demand, and that means we are slipping down the list."
Curevac is already producing its vaccine candidate, which is based on messenger RNA (mRNA) technology, at its plant in Tuebingen, Germany.
It has just struck a partnership with Swiss contract manufacturer Celonic Group, adding to earlier alliances with Novartis AG, Bayer AG, Fareva, Wacker and Rentschler Biopharma SE.
(Reporting by Douglas Busvine;Editing by Angus MacSwan)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Almost 100 detained at anti-government protest in Armenia, media say
- China's version of Neuralink unveiled at tech forum
- Construction boss accused of bribing Russian minister as scandal widens
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!